Pattern Pharma's P2PAR immunotherapeutic is effective against cancers and infectious diseases. It is a systemically administered TLR1, TLR2, TLR4 and TLR6 agonist which activates the innate immune system. P2PAR is the newly-patented successor of a first-generation product, which was developed by Pattern Founders and received regulatory approval in ex-US jurisdictions where it proved safe and efficacious during widespread use on patients. Pattern collaborates with Massachusetts General Hospital and MD Anderson and intends launching oncology clinical trials in 2021.

Pattern Pharma Inc. Logo



Event details

Date: June 10 - 17, 2021

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


30 in total